CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 92 filers reported holding CUE BIOPHARMA INC in Q1 2021. The put-call ratio across all filers is 4.24 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $722,170 | +11.3% | 313,987 | +76.6% | 0.00% | – |
| Q2 2023 | $649,120 | +52674.0% | 177,841 | -48.4% | 0.00% | -100.0% |
| Q1 2023 | $1,230 | +15.4% | 344,612 | -7.9% | 0.00% | 0.0% |
| Q4 2022 | $1,066 | -99.9% | 373,982 | -15.1% | 0.00% | 0.0% |
| Q3 2022 | $982,000 | -34.5% | 440,383 | -26.9% | 0.00% | 0.0% |
| Q2 2022 | $1,499,000 | +154.9% | 602,205 | +399.9% | 0.00% | – |
| Q1 2022 | $588,000 | -54.5% | 120,470 | +5.5% | 0.00% | -100.0% |
| Q4 2021 | $1,292,000 | +7.4% | 114,204 | +38.3% | 0.00% | 0.0% |
| Q3 2021 | $1,203,000 | -55.0% | 82,553 | -64.0% | 0.00% | -50.0% |
| Q2 2021 | $2,672,000 | +179.5% | 229,333 | +192.6% | 0.00% | +100.0% |
| Q1 2021 | $956,000 | -78.9% | 78,376 | -78.4% | 0.00% | -66.7% |
| Q4 2020 | $4,535,000 | +67.0% | 362,523 | +100.9% | 0.00% | 0.0% |
| Q3 2020 | $2,716,000 | -50.0% | 180,465 | -18.6% | 0.00% | -57.1% |
| Q2 2020 | $5,431,000 | +4541.9% | 221,583 | +1491.3% | 0.01% | – |
| Q3 2019 | $117,000 | +36.0% | 13,925 | +25.5% | 0.00% | – |
| Q1 2019 | $86,000 | – | 11,098 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |